StockNow
Log in
Global MarketsIMPORTANT

Novo Nordisk (NOVOB DC) Q2 (DKK): Adj. EBIT 33.4bln (exp. 28.9bln), raises 2026 adj. sales and operating profit outlook to between 0% to -6% at CER (exp. -5.9%)

StockNow breaking-news AI analysis

Novo Nordisk beat Q2 adjusted EBIT expectations and raised its 2026 outlook, driven by strong GLP-1 and Wegovy pill sales despite ongoing competitive and pricing pressures.

News detail

Q2 2026 adj sales up 7% at CER; adj operating profit up 11% at CER. Improved outlook is driven by increased expectations for GLP-1 product sales.

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday

Geopolitics

US Treasury official says the latest removal of sanctions on Iran is not indicative of any shift in US policy toward the Government of Iran, Fox's Heinrich reports

Fed

Fed's Kashkari (2026 voter, Hawkish dissenter) says now is the time to start slowly moving up rates, but not calling for dramatic rate hikes